CytomX Therapeutics, Inc. CTMX
Set alert
2.18 USD -0.05 -2.08%
As of Nov 3, 3:05 PM ET
2.18 Day range 2.32
2.14 52-week range 8.21
- YTD
- -48.74%
- 1 year
- -44.44%
- Open
- 2.25
- Prev close
- 2.23
- Mkt cap
- 476.11M
- Vol
- 2.46M
- Avg vol
- 3.59M
- EPS
- -0.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.18
- High
- 2.32
- Forward P/E
- -9.74
- Beta
- 2.48
- Short ratio
- 1.78
- Inst. own
- 75.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.92
- 200-d avg
- 3.77
- 1y target
- 13.67
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.67 +525.9% upside
Now 2.18
- Target (low)
- 11.00
- Target (mean)
- 13.67
- Target (high)
- 17.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 9
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.11499 | -0.16291 – -0.077 | 0.27 | -142.6% | 4.68M | -90.8% | 8 |
| Next quarter | -0.06686 | -0.15384 – 0.12 | 0.00 | 0.0% | 10.47M | -43.9% | 8 |
| Current year | -0.41703 | -0.69321 – -0.193 | -0.15 | -178.0% | 22.17M | -70.9% | 8 |
| Next year | -0.47309 | -0.69872 – -0.166 | -0.41703 | -13.4% | 18.73M | -15.5% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 23, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 19, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 18, 2026 | Jefferies | Maintained | Buy | Buy |
| Mar 18, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 17, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 16, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 16, 2026 | JP Morgan | Upgrade | Neutral | Overweight |
| Mar 9, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Feb 4, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Feb 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 20, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 20, 2026 | Guggenheim | Initiated | — | Buy |
| Jan 20, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 21, 2025 | Barclays | Maintained | Overweight | Overweight |
| Sep 22, 2025 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jul 31, 2025 | Oppenheimer | Initiated | — | Outperform |
| May 20, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| May 15, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Apr 14, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 7, 2025 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jan 7, 2025 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Sep 13, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Aug 22, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Jun 27, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 28, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
| May 9, 2024 | BMO Capital | Maintained | Market Perform | Market Perform |
| May 9, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |